<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mountzios, I.</style></author><author><style face="normal" font="default" size="100%">Bournakis, E.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Varkaris, A.</style></author><author><style face="normal" font="default" size="100%">Wen, S.</style></author><author><style face="normal" font="default" size="100%">Chrisofos, M.</style></author><author><style face="normal" font="default" size="100%">Deliveliotis, C.</style></author><author><style face="normal" font="default" size="100%">Alamanis, C.</style></author><author><style face="normal" font="default" size="100%">Anastasiou, I.</style></author><author><style face="normal" font="default" size="100%">Constantinides, C.</style></author><author><style face="normal" font="default" size="100%">Karadimou, A.</style></author><author><style face="normal" font="default" size="100%">Tsiatas, M.</style></author><author><style face="normal" font="default" size="100%">Papadimitriou, C.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer</style></title><secondary-title><style face="normal" font="default" size="100%">Urology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-79952360061&amp;doi=10.1016%2fj.urology.2010.08.044&amp;partnerID=40&amp;md5=4f193d53c7826dbc9aba8dc2b533ac79</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">77</style></volume><pages><style face="normal" font="default" size="100%">682 - 687</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objectives To determine whether intermittent docetaxel might control disease while limiting the toxicity and improving the quality-of-life parameters in patients with advanced, castrate-resistant prostate cancer. Intermittent docetaxel represents an appealing therapeutic approach. Methods We reviewed the records of 35 patients with chemotherapy-naive castrate-resistant prostate cancer who had received docetaxel 45 mg/m2 every 2 weeks, with oral prednisone 5 mg twice daily. Treatment was held when the patients had reached a &amp;gt;50% prostate-specific antigen reduction from baseline that was confirmed by a second measurement 4 weeks later, in the absence of disease progression. Docetaxel was resumed at a &amp;gt;25% prostate-specific antigen increase from the nadir level, also confirmed by a second measurement 4 weeks later, or in cases of documented disease progression. Results Of the 35 patients, 18 (51.42%) had entered the first chemotherapy-free interval (CFI) after a median of 6 infusions (range 2-12), 6 patients had entered a second CFI after a median of 4 months (range 2-12), and 1 patient, a third CFI at the last follow-up point. The median interval &quot;off chemotherapy&quot; was 4.5 months (range 1-16) for the first CFI. Two patients discontinued docetaxel because of Grade 4 nonhematologic toxicity. The median interval to treatment failure was 8.1 months (95% confidence interval 5.1-12.2) for the entire cohort and 12.2 months (95% confidence interval 8.3-25+) for the patients who had entered the first CFI. Conclusions The results of our study have shown that intermittent docetaxel is a clinically active and likely more tolerable and less costly therapeutic strategy for patients with castrate-resistant prostate cancer than continuous administration. Additional validation of this approach is warranted. © 2011 Elsevier Inc.</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><notes><style face="normal" font="default" size="100%">Cited By :14Export Date: 21 February 2017</style></notes></record></records></xml>